While disease-modifying therapies are widely used for patients with relapsing-remitting multiple sclerosis (RRMS) to reduce disability progression, there has been little to offer patients who transition to secondary progressive multiple sclerosis (SPMS), particularly when they reach the non-relapsing phase of the illness. The limbic spoke to neurologist Doctor Marion Simpson from the Austin Hospital in ...
Mayzent® (siponimod): the first reimbursed treatment for secondary progressive MS
8 Dec 2020
Sponsored by Novartis Pharmaceuticals Australia Pty Ltd